Andrew M. Luks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew M. Luks has a total of 298 co-authors. Here are the top co-authors by number of shared publications:
Erik R. Swenson
University of Washington Seattle, Washington
14 shared publicationsColin K. Grissom
Pulmonary and Critical Care Medicine, Intermountain Healthcare and the University of Utah, Salt Lake City, Utah, USA
6 shared publicationsKen Zafren
Department of Emergency Medicine, Stanford University School of Medicine, Stanford, CA
4 shared publicationsPeter H. Hackett
Altitude Research Center, Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
4 shared publicationsRobert B. Schoene
Division of Pulmonary and Critical Care Medicine, Sound Physicians, St. Mary's Medical Center and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, CA
4 shared publicationsGeorge W. Rodway
Department of Family Medicine–Sports Medicine, University of Nevada, Reno School of Medicine, Reno, NV
3 shared publications
Latest Publications
- 1 May 2026
- Published by Springer Nature
- p. 171-180
How to Give a Great PowerPoint Presentation
- 19 February 2026
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 27 (1) , 60-77
Pharmacological Prophylaxis and Supplemental Oxygen for Unacclimatized Rescuers at Very High Altitude: Scoping Review and 2025 Joint Recommendations of the International Commission for Mountain Emergency Medicine and the International Society for Mountain Medicine
McLaughlin, Kyle, Steve Roy, Marika Falla, Giacomo Strapazzon, Andrew M. Luks, Ken Zafren, Hermann Brugger, Martin Musi, Iztok Tomazin, John Ellerton, Ghan Bahadur Thapa, and Peter Paal. Pharmacological prophylaxis and supplemental oxygen for unacclimatized rescuers at very high altitude: scoping review and 2025 joint recommendations of the International Commission for Mountain Emergency Medicine and the International Society for Mountain Medicine. High Alt Med Biol. 27:60–77, 2026. Background: Mountain rescuers and pilots rapidly ascending to altitudes above 3,500 m are exposed to the detrimental effects of hypobaric hypoxia, including cognitive and physical impairment, as well as high-altitude illness (HAI). We conducted a scoping review of oxygen supplementation and pharmacologic measures to improve cognitive and physical performance and prevent HAI in unacclimatized rescuers rapidly ascending above 3,500 m during rescue missions. Methods: Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, 723 articles were screened, 133 reviewed and a total of 50 articles were included for data extraction, based on the intervention: 6 on oxygen, 29 on acetazolamide (AZ), 17 on dexamethasone (DEX), 3 on nifedipine, and 5 on phosphodiesterase-5 inhibitors. Discussion: Supplemental oxygen improves physical and cognitive performance at high altitude and is recommended for rapid ascent rescues >30 minutes between 3,500 and 4,000 m, and for rescues of any duration above 4,000 m. If oxygen is administered, pharmacological prophylaxis is not required. If oxygen is unavailable, AZ or DEX can be used for rapid ascent rescues above 3,500 m for longer than 3 hours to reduce the incidence and severity of acute mountain sickness. At altitudes above 5,000 m or for rescues requiring prolonged physical work, the use of both AZ and DEX is recommended. Conclusions: To enhance the safety and effectiveness of high-altitude rescues, we provide recommendations for the use of supplemental oxygen and pharmacologic prophylaxis to reduce the risk of HAI and improve cognitive and physical performance during rapid ascents to altitudes >3,500 m.
- 19 February 2026
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 27 (1) , 60-77
Pharmacological Prophylaxis and Supplemental Oxygen for Unacclimatized Rescuers at Very High Altitude: Scoping Review and 2025 Joint Recommendations of the International Commission for Mountain Emergency Medicine and the International Society for Mountain Medicine
McLaughlin, Kyle, Steve Roy, Marika Falla, Giacomo Strapazzon, Andrew M. Luks, Ken Zafren, Hermann Brugger, Martin Musi, Iztok Tomazin, John Ellerton, Ghan Bahadur Thapa, and Peter Paal. Pharmacological prophylaxis and supplemental oxygen for unacclimatized rescuers at very high altitude: scoping review and 2025 joint recommendations of the International Commission for Mountain Emergency Medicine and the International Society for Mountain Medicine. High Alt Med Biol. 27:60–77, 2026. Background: Mountain rescuers and pilots rapidly ascending to altitudes above 3,500 m are exposed to the detrimental effects of hypobaric hypoxia, including cognitive and physical impairment, as well as high-altitude illness (HAI). We conducted a scoping review of oxygen supplementation and pharmacologic measures to improve cognitive and physical performance and prevent HAI in unacclimatized rescuers rapidly ascending above 3,500 m during rescue missions. Methods: Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, 723 articles were screened, 133 reviewed and a total of 50 articles were included for data extraction, based on the intervention: 6 on oxygen, 29 on acetazolamide (AZ), 17 on dexamethasone (DEX), 3 on nifedipine, and 5 on phosphodiesterase-5 inhibitors. Discussion: Supplemental oxygen improves physical and cognitive performance at high altitude and is recommended for rapid ascent rescues >30 minutes between 3,500 and 4,000 m, and for rescues of any duration above 4,000 m. If oxygen is administered, pharmacological prophylaxis is not required. If oxygen is unavailable, AZ or DEX can be used for rapid ascent rescues above 3,500 m for longer than 3 hours to reduce the incidence and severity of acute mountain sickness. At altitudes above 5,000 m or for rescues requiring prolonged physical work, the use of both AZ and DEX is recommended. Conclusions: To enhance the safety and effectiveness of high-altitude rescues, we provide recommendations for the use of supplemental oxygen and pharmacologic prophylaxis to reduce the risk of HAI and improve cognitive and physical performance during rapid ascents to altitudes >3,500 m.
- 11 December 2025
- Published by Springer Nature
- p. C1
Correction to: The Lungs at the Extremes of Environment and Age
- 11 December 2025
- Published by Springer Nature
- p. C1
Correction to: The Lungs at the Extremes of Environment and Age
- 1 December 2025
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 26 (4) , 339-346
Ignoble Gas: The Questionable Role of Xenon in Rapid Ascents of Mount Everest
Manferdelli, Giorgio, Marc M. Berger, and Andrew M. Luks. Ignoble gas: The questionable role of xenon in rapid ascents of Mount Everest. High Alt Med Biol. 26:339–346, 2025.—Beyond the logistical, technical, and physiological challenges associated with climbing extremely high mountains such as Mount Everest, an important feature of such expeditions is their long duration. Among the strategies used in recent years to reduce expedition duration, one particularly novel approach was implemented during Everest expeditions in 2024 and 2025—inhalation of the noble gas xenon prior to the expeditions. Despite the tremendous attention this approach received in the media, significant questions remain as to whether it is truly effective at improving acclimatization and shortening the duration of expeditions. This review examines this issue in greater detail. After providing background information on xenon, the review examines potential rationales for xenon’s use in the mountains, assesses the risks of xenon administration, and considers other aspects of the expedition protocol that likely affected the odds of summit success. Based on this analysis, there is no basis for widespread implementation of xenon inhalation at this time. Evidence of benefit is lacking, and there are strong reasons to believe other aspects of the expedition protocol contributed significantly to the expeditions’ outcomes. Much further research on these questions is warranted before any more climbers should engage in this potentially risky practice.
- 1 December 2025
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 26 (4) , 339-346
Ignoble Gas: The Questionable Role of Xenon in Rapid Ascents of Mount Everest
Manferdelli, Giorgio, Marc M. Berger, and Andrew M. Luks. Ignoble gas: The questionable role of xenon in rapid ascents of Mount Everest. High Alt Med Biol. 26:339–346, 2025.—Beyond the logistical, technical, and physiological challenges associated with climbing extremely high mountains such as Mount Everest, an important feature of such expeditions is their long duration. Among the strategies used in recent years to reduce expedition duration, one particularly novel approach was implemented during Everest expeditions in 2024 and 2025—inhalation of the noble gas xenon prior to the expeditions. Despite the tremendous attention this approach received in the media, significant questions remain as to whether it is truly effective at improving acclimatization and shortening the duration of expeditions. This review examines this issue in greater detail. After providing background information on xenon, the review examines potential rationales for xenon’s use in the mountains, assesses the risks of xenon administration, and considers other aspects of the expedition protocol that likely affected the odds of summit success. Based on this analysis, there is no basis for widespread implementation of xenon inhalation at this time. Evidence of benefit is lacking, and there are strong reasons to believe other aspects of the expedition protocol contributed significantly to the expeditions’ outcomes. Much further research on these questions is warranted before any more climbers should engage in this potentially risky practice.
- 1 September 2025
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 26 (3) , 237-241
Clinical Conundrum: Climbing at the Extremes of High Elevation with Nonischemic Cardiomyopathy
Cornwell, William, Aaron L. Baggish, Christoph Dehnert, Benjamin D. Levine, and Andrew M. Luks. Clinical conundrum: climbing at the extremes of high elevation with nonischemic cardiomyopathy. High Alt Med Biol. 26:237-241, 2025.
- 1 September 2025
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 26 (3) , 237-241
Clinical Conundrum: Climbing at the Extremes of High Elevation with Nonischemic Cardiomyopathy
Cornwell, William, Aaron L. Baggish, Christoph Dehnert, Benjamin D. Levine, and Andrew M. Luks. Clinical conundrum: climbing at the extremes of high elevation with nonischemic cardiomyopathy. High Alt Med Biol. 26:237-241, 2025.
- 1 July 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (7) , 1079-1083
The Right Diagnosis Comes to Those Who Measure Correctly
- 1 July 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (7) , 1079-1083
The Right Diagnosis Comes to Those Who Measure Correctly
- 1 December 2024
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 25 (4) , 337-341
Clinical Conundrum: Return to High Altitude After Cerebral Venous Sinus Thrombosis
Luks, Andrew M., Thomas G. DeLoughery, Jeffrey H. Gertsch, and Suzy Stokes. Clinical conundrum: return to high altitude after cerebral venous sinus thrombosis. High Alt Med Biol. 00:00-00, 2024.
- 1 December 2024
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 25 (4) , 337-341
Clinical Conundrum: Return to High Altitude After Cerebral Venous Sinus Thrombosis
Luks, Andrew M., Thomas G. DeLoughery, Jeffrey H. Gertsch, and Suzy Stokes. Clinical conundrum: return to high altitude after cerebral venous sinus thrombosis. High Alt Med Biol. 00:00-00, 2024.
- 8 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (15) , 1158-1160
All That Is Gold Does Not Glitter
- 8 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (15) , 1158-1160
All That Is Gold Does Not Glitter
- 1 September 2024
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 25 (3) , 238-246
Evaluation and Management of the Individual with Recurrent High Altitude Pulmonary Edema
Luks AM, Grissom CK. Evaluation and Management of the Individual with Recurrent HAPE. High Alt Med Biol. 25:238–246, 2024. Individuals with a history of acute altitude illness often seek recommendations from medical providers on how to prevent such problems on future ascents to high elevation. Although many of these cases can be managed with pharmacologic prophylaxis and counseling about the appropriate rate of ascent alone, there are some situations in which further diagnostic evaluation may also be warranted. One such situation is the individual with recurrent episodes of high altitude pulmonary edema (HAPE), as one of several predisposing factors may be present that warrants additional interventions beyond pharmacologic prophylaxis and slow ascent and may even preclude future travel to high altitude. This review considers this situation in greater detail. Structured around the case of an otherwise healthy 27-year-old individual with recurrent episodes of HAPE who would like to climb Denali (6,190 m), the review examines the known risk factors for disease and then provides guidance regarding when and how to evaluate such individuals and appropriate steps to prevent HAPE on further ascents to high elevation. Except in rare circumstances, a history of recurrent HAPE does not preclude further ascent to high elevation, as a multipronged approach including pharmacologic prophylaxis, careful planning about the rate of ascent, and the degree of physical effort and other strategies, such as preacclimatization, staged ascent, and use of hypoxic tents, can be employed to reduce the risk of recurrence with future travel.
- 1 September 2024
- Published by SAGE Publications in High Altitude Medicine & Biology
- Vol. 25 (3) , 238-246
Evaluation and Management of the Individual with Recurrent High Altitude Pulmonary Edema
Luks AM, Grissom CK. Evaluation and Management of the Individual with Recurrent HAPE. High Alt Med Biol. 25:238–246, 2024. Individuals with a history of acute altitude illness often seek recommendations from medical providers on how to prevent such problems on future ascents to high elevation. Although many of these cases can be managed with pharmacologic prophylaxis and counseling about the appropriate rate of ascent alone, there are some situations in which further diagnostic evaluation may also be warranted. One such situation is the individual with recurrent episodes of high altitude pulmonary edema (HAPE), as one of several predisposing factors may be present that warrants additional interventions beyond pharmacologic prophylaxis and slow ascent and may even preclude future travel to high altitude. This review considers this situation in greater detail. Structured around the case of an otherwise healthy 27-year-old individual with recurrent episodes of HAPE who would like to climb Denali (6,190 m), the review examines the known risk factors for disease and then provides guidance regarding when and how to evaluate such individuals and appropriate steps to prevent HAPE on further ascents to high elevation. Except in rare circumstances, a history of recurrent HAPE does not preclude further ascent to high elevation, as a multipronged approach including pharmacologic prophylaxis, careful planning about the rate of ascent, and the degree of physical effort and other strategies, such as preacclimatization, staged ascent, and use of hypoxic tents, can be employed to reduce the risk of recurrence with future travel.
- Open Access
- 29 July 2024
- Published by Wiley in The Journal of Physiology
- Vol. 602 (21) , 5785-5800
Avalanche burial pathophysiology – a unique combination of hypoxia, hypercapnia and hypothermia
For often unclear reasons, the survival times of critically buried avalanche victims vary widely from minutes to hours. Individuals can survive and sustain organ function if they can breathe under the snow and maintain sufficient delivery of oxygen and efflux of carbon dioxide. We review the physiological responses of humans to critical avalanche burial, a model which shares similarities and differences with apnoea and accidental hypothermia. Within a few minutes of burial, an avalanche victim is exposed to hypoxaemia and hypercapnia, which have important effects on the respiratory and cardiovascular systems and pose a major threat to the central nervous system. As burial time increases, an avalanche victim also develops hypothermia. Despite progressively reduced metabolism, reduced oxygen and increased carbon dioxide tensions may exacerbate the pathophysiological consequences of hypothermia. Hypercapnia seems to be the main cause of cardiovascular instability, which, in turn, is the major reason for reduced cerebral oxygenation despite reductions in cerebral metabolic activity caused by hypothermia. ‘Triple H syndrome’ refers to the interaction of hypoxia, hypercapnia and hypothermia in a buried avalanche victim. Future studies should investigate how the respiratory gases entrapped in the porous snow structure influence the physiological responses of buried individuals and how haemoconcentration, blood viscosity and cell deformability affect blood flow and oxygen delivery. Attention should also be devoted to identifying strategies to prolong avalanche survival by either mitigating hypoxia and hypercapnia or reducing core temperature so that neuroprotection occurs before the onset of cerebral hypoxia. image
- 29 July 2024
- Published by Wiley in The Journal of Physiology
- Vol. 602 (21) , 5785-5800
Open AccessAvalanche burial pathophysiology – a unique combination of hypoxia, hypercapnia and hypothermia
For often unclear reasons, the survival times of critically buried avalanche victims vary widely from minutes to hours. Individuals can survive and sustain organ function if they can breathe under the snow and maintain sufficient delivery of oxygen and efflux of carbon dioxide. We review the physiological responses of humans to critical avalanche burial, a model which shares similarities and differences with apnoea and accidental hypothermia. Within a few minutes of burial, an avalanche victim is exposed to hypoxaemia and hypercapnia, which have important effects on the respiratory and cardiovascular systems and pose a major threat to the central nervous system. As burial time increases, an avalanche victim also develops hypothermia. Despite progressively reduced metabolism, reduced oxygen and increased carbon dioxide tensions may exacerbate the pathophysiological consequences of hypothermia. Hypercapnia seems to be the main cause of cardiovascular instability, which, in turn, is the major reason for reduced cerebral oxygenation despite reductions in cerebral metabolic activity caused by hypothermia. ‘Triple H syndrome’ refers to the interaction of hypoxia, hypercapnia and hypothermia in a buried avalanche victim. Future studies should investigate how the respiratory gases entrapped in the porous snow structure influence the physiological responses of buried individuals and how haemoconcentration, blood viscosity and cell deformability affect blood flow and oxygen delivery. Attention should also be devoted to identifying strategies to prolong avalanche survival by either mitigating hypoxia and hypercapnia or reducing core temperature so that neuroprotection occurs before the onset of cerebral hypoxia. image